Partnerships
Empowering and connecting cancer organisations from around the world
Moving from one-to-one partnerships to Industry partnerships
Many organisations do not have the resources to be connected to UICC’s networks and participate in its signature events. UICC’s long-standing partners MSD and the Canadian Partnership Against Cancer (CPAC) have been able to help us address this gap by empowering and connecting these organisations with hundreds of others by sponsoring UICC membership and opening doors to UICC benefits such as capacity building, travel grants and opportunities to engage and connect at the global level.
For the last few years, UICC has developed a significant number of effective shared value relationships with international companies and organisations, working on areas of common interest. In 2016, we moved into a new paradigm - exploring opportunities that demand collective action. We have entered into a three-year partnership with 22 pharmaceutical companies, three leading radiotherapy companies, and two cancer treatment centre builders to support UICC’s new initiative C/Can 2025: City Cancer Challenge. This represents a major shift in the way we anticipate working with partners in future - identifying common challenges which can only be addressed through collective rather than bilateral action.
Bridging the divide between sectors and creating effective partnerships Thanks to the strong collaboration with Bupa, The Partnering Initiative (TPI) and the involvement of CEOs of leading UICC member organisations, UICC launched a partnering guidebook specifically designed to help cancer and non-communicable disease organisations to partner effectively with the private sector. The guidebook provides best practices and cases studies of how other organisations have partnered with businesses in ways which have had a positive impact on the health of various communities.
2016 UICC Annual Report
“At Astellas we have a social responsibility to improve access to better health for patients worldwide, and UICC has provided us with an international platform to achieve this. Being a Vanguard Partner has been extremely valuable in positioning us as a leading player in the global fight against cancer.” Peter Sandor, VP Global Oncology Strategy, Astellas
9